Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma.

@article{Zain2012RoleOH,
  title={Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma.},
  author={Jasmine M. Zain},
  journal={Hematology/oncology clinics of North America},
  year={2012},
  volume={26 3},
  pages={671-704, ix}
}
Histone deacetylase inhibitors (HDACI) have allowed pharmacologic manipulation of deregulated genes in cancer cells and have shown single-agent activity against T cell lymphomas, cutaneous T cell lymphomas, mantle cell lymphomas, and Hodgkin disease. The bigger promise of these agents is in enhancing the activity of other targeted therapies. In addition, the effects of HDACI on the immune system and cytokines indicate that HDACI can be useful in the treatment of immune dysfunction underlying… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 177 references

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.

Proceedings of the National Academy of Sciences of the United States of America • 2004
View 5 Excerpts
Highly Influenced

Covalent modifications of histones: expression from chromatin templates.

Current opinion in genetics & development • 1998
View 4 Excerpts
Highly Influenced

Pooled analyses of two international, multicenter clinical studies of romidepsin in 167 patients with cutaneous T-cell lymphoma (CTCL).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2009
View 4 Excerpts
Highly Influenced

Isotype-selective HDAC-inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical HL [abstract: 2566

A. Younes
Blood • 2007
View 8 Excerpts
Highly Influenced

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2007
View 5 Excerpts
Highly Influenced

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2003
View 7 Excerpts
Highly Influenced

The proteasome: structure, function, and role in the cell.

Cancer treatment reviews • 2003
View 6 Excerpts
Highly Influenced

Care of the adult Hodgkin lymphoma survivor.

The American journal of medicine • 2011
View 1 Excerpt

Similar Papers

Loading similar papers…